RXi Pharmaceuticals Corp. (NASDAQ:RXII) had its price target cut by S&P Equity Research from $2.35 to $1.71 in a report released on Monday.

RXi Pharmaceuticals Corp. (NASDAQ:RXII) opened at 2.2334 on Monday. The firm’s market capitalization is $14.65 million. RXi Pharmaceuticals Corp. has a 52 week low of $0.94 and a 52 week high of $4.35. The stock has a 50 day moving average price of $1.32 and a 200-day moving average price of $2.02.

RXi Pharmaceuticals Corp. (NASDAQ:RXII) last issued its quarterly earnings data on Thursday, November 10th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.34). During the same period in the previous year, the company posted ($0.40) earnings per share. Analysts anticipate that RXi Pharmaceuticals Corp. will post ($1.25) EPS for the current fiscal year.

About RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

5 Day Chart for NASDAQ:RXII

Receive News & Stock Ratings for RXi Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corp. and related stocks with our FREE daily email newsletter.